TT
Typewriter Therapeutics, Inc.
SEC filingBiotechnology · Cambridge, MA
Amount raised$56.3Msold at filing
Total offering$56.3M
Investors in the raise6count reported to the SEC
FiledSep 21, 2026first sale Jan 8, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Laura TadvalkarDirector
Matthew StantonExecutive Officer, Director
Kenneth HorneDirector
Mikael DolstonDirector
Executive officers, directors and promoters as listed on the Form D.